This approach has been already successfully implemented for the diagnosis and therapy of Neuro-Endocrine Tumors (Lutathera®/NETSPOT®) [10] and prostate cancers ([68Ga]Ga-PSMA-11/[177Lu]Lu-PSMA-617) [11]. Here, FOLH1 is linked to prostate carcinoma.